List of Aptiom drug patents

Aptiom is owned by Sunovion Pharms Inc.

Aptiom contains Eslicarbazepine Acetate.

Aptiom has a total of 11 drug patents out of which 0 drug patents have expired.

Aptiom was authorised for market use on 08 November, 2013.

Aptiom is available in tablet;oral dosage forms.

Aptiom can be used as treatment of partial-onset seizures; treatment of partial-onset seizures in a patient with refractory partial-onset seizures, treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine, treatment of partial-onset seizures, treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; treatment of partial-onset seizures, treatment of partial-onset seizures in a patient with refractory partial-onset seizures; treatment of partial-onset seizures.

The generics of Aptiom are possible to be released after 24 August, 2032.

Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9206135 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11364247 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(2 years from now)

US10702536 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(2 years from now)

US10695354 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(2 years from now)

US10675287 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate
May, 2025

(2 years from now)

US9643929 SUNOVION PHARMS INC Asymmetric catalytic reduction of oxcarbazepine
Apr, 2026

(3 years from now)

US9763954 SUNOVION PHARMS INC Therapeutical uses of eslicarbazepine
Sep, 2028

(5 years from now)

US9566244 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(5 years from now)

US10912781 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Oct, 2028

(5 years from now)

US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Apr, 2030

(7 years from now)

US9750747 SUNOVION PHARMS INC Treatments involving eslicarbazepine acetate or eslicarbazepine
Aug, 2032

(9 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine; Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's patent expiration?
More Information on Dosage

APTIOM family patents

25

United States

7

Japan

7

Portugal

7

European Union

5

Korea, Republic of

5

Spain

5

Mexico

5

Canada

4

Brazil

4

Australia

4

Argentina

4

Russia

3

Poland

3

Cyprus

3

Slovenia

3

United Kingdom

3

China

3

Denmark

2

RS

2

Lithuania

2

Ukraine

2

Hungary

2

South Africa

2

Croatia

2

New Zealand

1

Austria

1

IB

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic